Scribe Therapeutics Inc. (SCTX)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	36.28M +86.7%
Net Income	-35.73M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SCTX

Scribe Therapeutics is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic me...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: SCTX
• Website: https://www.scribetx.com/

Financial Performance

Financial numbers in USD

Data Source: SEC filings Last updated: Jul 9, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error